# US 2023/0265126 A1 · Ubiquitin high affinity cyclic peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265126 A1
- Document ID: US20230265126A1
- Status: Published application
- Kind: A1
- Application number: 17/982,883
- Filed: 2022-11-08
- Published: 2023-08-24
- Earliest claimed: 2018-06-06
- Assignees: Technion Research & Development Foundation Limited; The University of Tokyo
- Applicants: Technion Research & Development Foundation Limited; The University of Tokyo
- Inventors: Ashraf BRIK; Mickal NAWATHA; Hiroaki SUGA; Joseph ROGERS
- Web page: https://patentgrep.com/patent/US20230265126A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 35/00: Antineoplastic agents
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to a cyclic polypeptide having ubiquitin binding affinity (KD) of 0.1-100 nM. Further provided are methods for reducing deubiquitination activity of a cell, and for treating cancer in a subject in need thereof.

## Claims

### Claim 1

A cyclic polypeptide comprising an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 4)
LYLDDX1GDWWIC;
(SEQ ID NO: 1)
WYDX1EYYYLGYGC;
(SEQ ID NO: 2)
GWFDNLYWYVX1X1C;
and
(SEQ ID NO: 3)
GWFDDX2YX3X4X5AYC;
wherein X1 is an amino acid selected from: (i) naturally occurring amino acids; or (ii) non-naturally occurring amino acids, and wherein X2 is an amino acid selected from the group consisting of: Leu, Gln, Thr, Asn, Glu, and Asp, and wherein X3 is an amino acid selected from the group consisting of: Leu, and Tyr, and wherein X4 is an amino acid selected from the group consisting of: Phe and Tyr, and wherein X5 is an amino acid selected from the group consisting of: Val and Leu.

### Claim 2 (depends on 1)

The cyclic polypeptide of claim 1, wherein any one of the amino acid sequences set forth in SEQ ID Nos: 1-4 further comprises a Trp amino acid residue at the N′ terminus.

### Claim 3 (depends on 1)

The cyclic polypeptide of claim 1, wherein any one of the amino acid sequences set forth in SEQ ID Nos: 1-4 further comprises a Gly amino acid reside at the C′ terminus.

### Claim 4 (depends on 1)

The cyclic polypeptide of claim 1, comprising the amino acid sequences as set forth in any one of: WWYDX1EYYYLGYGCG (SEQ ID NO: 14); WGWFDNLYWYVX1X1CG (SEQ ID NO: 15); WGWFDDX2YX3X4X5AYCG (SEQ ID NO: 16); WLYLDDX1GDWWICG (SEQ ID NO: 17).

### Claim 5 (depends on 1)

The cyclic polypeptide of claim 1, wherein said non-naturally occurring amino acid is selected from the group consisting of: Abu, Nva, Nle, Ahp, Aoc, TMe, hSM, tBu, Cpa, Cha, Alb, MeG, MeA, MeB, MeF, 2Th, 3Th, YMe, 2Np, Bzt and DAl.

### Claim 6 (depends on 1)

The cyclic polypeptide of claim 1, comprising an amino acid sequence selected from the group consisting of: GWFDDQYLFVAYC (SEQ ID NO: 18); GWFDDTYLFVAYC (SEQ ID NO: 19); GWFDDNYLFVAYC (SEQ ID NO: 20); GWFDDEYLFVAYC (SEQ ID NO: 21); GWFDDDYLFVAYC (SEQ ID NO: 22); GWFDDLYWFVAYC (SEQ ID NO: 23); GWFDDLYYFVAYC (SEQ ID NO: 24); GWFDDLYLYVAYC (SEQ ID NO: 25); GWFDDLYLFYAYC (SEQ ID NO: 26); GWFDDLYLFLAYC (SEQ ID NO: 27); GWFDDEYWFYAYC (SEQ ID NO: 28); GWFDDLYWYYAYC (SEQ ID NO: 29); GWFDDEYWYYAYC (SEQ ID NO: 30); GWFDDQYWYYAYC (SEQ ID NO: 31); GWFDDNYWYYAYC (SEQ ID NO: 32); GWFDDHYWYYAYC (SEQ ID NO: 33); GWFDDKYWYYAYC (SEQ ID NO: 34); and GWFDDLYLFVAYC (SEQ ID NO: 45).

### Claim 7 (depends on 1)

The cyclic polypeptide of claim 1, wherein: (i) said polypeptide comprises not more than 16 amino acid residues; (ii) the amino acid at position one is a D amino acid, or a combination thereof.

### Claim 8 (depends on 1)

The cyclic polypeptide of claim 1, wherein the amino acid at position one is conjugated to a cyclizing molecule, and optionally wherein said cyclizing molecule is selected from the group consisting of: chloracetyl chloride, 3-chlorobenzoyl (3-ClBz), 4-chlorobenzoyl (4-ClBz) or Cl2SAc, and optionally wherein said cyclic polypeptide is prepared using a cyclizing molecule comprising a halogen.

### Claim 9 (depends on 1)

The cyclic polypeptide of claim 1, wherein said cyclic polypeptide is characterized as having: cell penetration capability, ubiquitin (Ub) binding capability, increased affinity to Ub compared to control, or any combination thereof, and optionally wherein said increased affinity is binding affinity KD of 0.05-100 nM.

### Claim 10 (depends on 1)

A composition comprising the cyclic polypeptide of claim 1, and at least one acceptable carrier or diluent.

### Claim 11

A method for ameliorating or treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a cyclic polypeptide, wherein said cyclic polypeptide binds ubiquitin with an affinity KD of 0.05-100 nM, wherein said cyclic polypeptide comprises not more than 16 amino acid residues, and wherein at least 55% of amino acids of said cyclic polypeptide are selected from the group consisting of: W, G, F, D, L, Y and C.

### Claim 12 (depends on 11)

The method of claim 11, wherein:
(i) said cyclic polypeptide is selected from the group consisting of:
(SEQ ID NO: 1)
WYDXEYYYLGYGC;
(SEQ ID NO: 2)
GWFDNLYWYVX1X1C;
(SEQ ID NO: 3)
GWFDDX2YX3X4X5AYC;
and
(SEQ ID NO: 4)
LYLDDX1GDWWIC;
wherein X1 is an amino acid selected from: (i) naturally occurring amino acids; or
(ii) non-naturally occurring amino acids, X2 is an amino acid selected from the group consisting of: Leu, Gln, Thr, Asn, Glu, and Asp, X3 is an amino acid selected from the group consisting of: Leu, and Tyr, X4 is an amino acid selected from the group consisting of: Phe and Tyr, X5 is an amino acid selected from the group consisting of: Val and Leu; X6 is an amino acid selected from the group consisting of: Tyr or Leu, X7 is an amino acid selected from the group consisting of: Tyr or His, X8 is an amino acid selected from the group consisting of: Thr or Ile, X9 is an amino acid selected from the group consisting of: Gly or Ala, and X10 is an amino acids selected from the group consisting of: Val or Leu;
(iii) any one of the amino acid sequences set forth in SEQ ID Nos: 1-4 further comprises a Trp amino acid reside at the N′ terminus;
any one of the amino acid sequences set forth in SEQ ID Nos: 1-4 further comprises a Gly amino acid reside at the C′ terminus;
(iv) said cyclic polypeptide comprises an amino acid sequences as set forth in
(SEQ ID NO: 14)
WWYDX1EYYYLGYGCG;
(SEQ ID NO: 15)
WGWFDNLYWYVX1X1CG;
(SEQ ID NO: 16)
WGWFDDX2YX3X4X5AYCG;
(SEQ ID NO: 17)
WLYLDDX1GDWWICG;
(v) said cyclic polypeptide comprises an amino acid sequence selected from the group consisting of: GWFDDQYLFVAYC (SEQ ID NO: 18); GWFDDTYLFVAYC (SEQ ID NO: 19); GWFDDNYLFVAYC (SEQ ID NO: 20); GWFDDEYLFVAYC (SEQ ID NO: 21); GWFDDDYLFVAYC (SEQ ID NO: 22); GWFDDLYWFVAYC (SEQ ID NO: 23); GWFDDLYYFVAYC (SEQ ID NO: 24); GWFDDLYLYVAYC (SEQ ID NO: 25); GWFDDLYLFYAYC (SEQ ID NO: 26); GWFDDLYLFLAYC (SEQ ID NO: 27); GWFDDEYWFYAYC (SEQ ID NO: 28); GWFDDLYWYYAYC (SEQ ID NO: 29); GWFDDEYWYYAYC (SEQ ID NO: 30); GWFDDQYWYYAYC (SEQ ID NO: 31); GWFDDNYWYYAYC (SEQ ID NO: 32); GWFDDHYWYYAYC (SEQ ID NO: 33); GWFDDKYWYYAYC (SEQ ID NO: 34); and GWFDDLYLFVAYC (SEQ ID NO: 45);
(vi) said non-naturally occurring amino acid is selected from the group consisting of: Abu, Nva, Nle, Ahp, Aoc, TMe, hSM, tBu, Cpa, Cha, Alb, MeG, MeA, MeB, MeF, 2Th, 3Th, YMe, 2Np, Bzt and Dal;
(vii) said amino acid at position one is a D amino acid;
(viii) said amino acid at position one of said cyclic polypeptide is conjugated to a cyclizing molecule;
(ix) said cyclizing molecule is selected from the group consisting of: chloracetyl chloride, 3-chlorobenzoyl (3-ClBz), 4-chlorobenzoyl (4-ClBz) or Cl2SAc;
(x) said cyclic polypeptide is prepared using a cyclizing molecule comprising a halogen;
(xi) said cyclic polypeptide has: cell penetrating capability, Ub binding capability, or a combination thereof;
(xii) said cyclic polypeptide has increased affinity to Ub compared to control;
(xiii) said Ub is a polymeric Ub;
(xiv) said polymeric Ub comprises Ub monomers linked at their K48 position (K48Ub);
(xv) said cyclic polypeptide reduces deubiquitination activity of a cell by at least 30%;
(xvi) said cyclic polypeptide reduces ubiquitinated proteins proteasomal degradation rate by at least 40%;
(xvii) said cyclic polypeptide has increased pro-apoptotic activity compared to control;
(xviii) said increased pro-apoptotic activity results in at least 20% more cell apoptosis compared to control; or
(xix) any combination of (i) to (xviii).

### Claim 13 (depends on 12)

The method of claim 12, wherein said cyclic polypeptide reduces cell viability with an IC50 of 0.05-15 μM.
